source
- SimBioSys receives FDA clearance for Nvidia-powered AI tool to predict breast cancer recurrenceSimBioSys announced FDA clearance for its TumorSight Risk platform, an AI-driven tool that uses MRI, pathology and clinical data to assess the likelihood of breast cancer returning. The cloud-base…
- Osivax’s flu vaccine OVX836 misses primary efficacy goal in phase 2b trialOsivax announced that its influenza A vaccine candidate OVX836 failed to meet the primary efficacy endpoint in a phase 2b trial involving 2,850 healthy adults in Europe. The trial showed a vaccine…